![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BCL2L2 |
Gene summary for BCL2L2 |
![]() |
Gene information | Species | Human | Gene symbol | BCL2L2 | Gene ID | 599 |
Gene name | BCL2 like 2 | |
Gene Alias | BCL-W | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92843 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
599 | BCL2L2 | C04 | Human | Oral cavity | OSCC | 1.46e-15 | 5.74e-01 | 0.2633 |
599 | BCL2L2 | C21 | Human | Oral cavity | OSCC | 1.44e-15 | 4.77e-01 | 0.2678 |
599 | BCL2L2 | C30 | Human | Oral cavity | OSCC | 4.14e-24 | 9.69e-01 | 0.3055 |
599 | BCL2L2 | C43 | Human | Oral cavity | OSCC | 1.92e-04 | 1.24e-01 | 0.1704 |
599 | BCL2L2 | C51 | Human | Oral cavity | OSCC | 1.06e-12 | 5.70e-01 | 0.2674 |
599 | BCL2L2 | C57 | Human | Oral cavity | OSCC | 7.81e-04 | 1.60e-01 | 0.1679 |
599 | BCL2L2 | C08 | Human | Oral cavity | OSCC | 9.97e-04 | 1.27e-01 | 0.1919 |
599 | BCL2L2 | SYSMH1 | Human | Oral cavity | OSCC | 4.60e-04 | 1.61e-01 | 0.1127 |
599 | BCL2L2 | SYSMH2 | Human | Oral cavity | OSCC | 2.71e-11 | 2.16e-01 | 0.2326 |
599 | BCL2L2 | SYSMH3 | Human | Oral cavity | OSCC | 1.28e-10 | 2.66e-01 | 0.2442 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
GO:200124220 | Oral cavity | OSCC | regulation of intrinsic apoptotic signaling pathway | 123/7305 | 164/18723 | 5.71e-21 | 9.77e-19 | 123 |
GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
GO:000683918 | Oral cavity | OSCC | mitochondrial transport | 162/7305 | 254/18723 | 8.96e-16 | 6.52e-14 | 162 |
GO:009719120 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway | 142/7305 | 219/18723 | 7.34e-15 | 4.55e-13 | 142 |
GO:000700610 | Oral cavity | OSCC | mitochondrial membrane organization | 85/7305 | 116/18723 | 6.29e-14 | 3.40e-12 | 85 |
GO:200124320 | Oral cavity | OSCC | negative regulation of intrinsic apoptotic signaling pathway | 73/7305 | 98/18723 | 9.33e-13 | 4.22e-11 | 73 |
GO:000863718 | Oral cavity | OSCC | apoptotic mitochondrial changes | 78/7305 | 107/18723 | 1.06e-12 | 4.78e-11 | 78 |
GO:001082117 | Oral cavity | OSCC | regulation of mitochondrion organization | 97/7305 | 144/18723 | 4.78e-12 | 1.83e-10 | 97 |
GO:000863018 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway in response to DNA damage | 72/7305 | 99/18723 | 9.50e-12 | 3.50e-10 | 72 |
GO:000183616 | Oral cavity | OSCC | release of cytochrome c from mitochondria | 46/7305 | 59/18723 | 1.17e-09 | 2.87e-08 | 46 |
GO:001063918 | Oral cavity | OSCC | negative regulation of organelle organization | 190/7305 | 348/18723 | 2.12e-09 | 4.97e-08 | 190 |
GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
GO:00905598 | Oral cavity | OSCC | regulation of membrane permeability | 54/7305 | 78/18723 | 6.05e-08 | 1.09e-06 | 54 |
GO:00901997 | Oral cavity | OSCC | regulation of release of cytochrome c from mitochondria | 37/7305 | 48/18723 | 8.67e-08 | 1.52e-06 | 37 |
GO:00469028 | Oral cavity | OSCC | regulation of mitochondrial membrane permeability | 45/7305 | 63/18723 | 1.80e-07 | 2.92e-06 | 45 |
GO:006145817 | Oral cavity | OSCC | reproductive system development | 217/7305 | 427/18723 | 3.75e-07 | 5.63e-06 | 217 |
GO:004860816 | Oral cavity | OSCC | reproductive structure development | 214/7305 | 424/18723 | 8.58e-07 | 1.18e-05 | 214 |
GO:00380346 | Oral cavity | OSCC | signal transduction in absence of ligand | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCL2L2 | insertion | Frame_Shift_Ins | novel | c.564_565insT | p.Ala191CysfsTer2 | p.A191Cfs*2 | Q92843 | protein_coding | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
BCL2L2 | SNV | Missense_Mutation | novel | c.328N>C | p.Ser110Arg | p.S110R | Q92843 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-CV-7253-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
BCL2L2 | SNV | Missense_Mutation | c.138N>A | p.Met46Ile | p.M46I | Q92843 | protein_coding | deleterious(0.01) | possibly_damaging(0.555) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
BCL2L2 | SNV | Missense_Mutation | rs746534702 | c.476N>T | p.Ala159Val | p.A159V | Q92843 | protein_coding | tolerated(0.35) | benign(0.071) | TCGA-HU-A4GU-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
BCL2L2 | SNV | Missense_Mutation | rs746534702 | c.476C>T | p.Ala159Val | p.A159V | Q92843 | protein_coding | tolerated(0.35) | benign(0.071) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
BCL2L2 | insertion | Frame_Shift_Ins | novel | c.564_565insT | p.Ala191CysfsTer2 | p.A191Cfs*2 | Q92843 | protein_coding | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | NAVITOCLAX | NAVITOCLAX | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL443684 | NAVITOCLAX | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | BORTEZOMIB | BORTEZOMIB | 15813915 | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | 2-CDA | CLADRIBINE | 15813915 | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166532 | ABT 737 | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL2107358 | OBATOCLAX MESYLATE | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ABT-263 | NAVITOCLAX | ||
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166530 | VENETOCLAX | |
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | PMID27744724-Compound-18 | |||
599 | BCL2L2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | NAVITOCLAX, ABT-263 |
Page: 1 |